These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 11548912

  • 1. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 2. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries.
    Ghatnekar O, Willis M, Persson U.
    J Wound Care; 2002 Feb; 11(2):70-4. PubMed ID: 11901743
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 Feb; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR, Gilligan AM, Motley TA.
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [Abstract] [Full Text] [Related]

  • 7. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 8. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
    Su HY, Yang CY, Ou HT, Chen SG, Chen JC, Ho HJ, Kuo S.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2250639. PubMed ID: 36633847
    [Abstract] [Full Text] [Related]

  • 10. The cost effectiveness of Apligraf treatment of diabetic foot ulcers.
    Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z.
    Pharmacoeconomics; 2003 Jan 03; 21(16):1171-83. PubMed ID: 14594438
    [Abstract] [Full Text] [Related]

  • 11. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Jan 03; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Jan 03; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 03; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 May 03; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 15. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A, Rogowski W.
    BMC Health Serv Res; 2009 Jul 10; 9():115. PubMed ID: 19591680
    [Abstract] [Full Text] [Related]

  • 16. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Jul 10; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 17. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Jul 10; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 18. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan 10; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 19. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 20. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb 01; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.